Marc Beer Is On a Mission To Improve The Lives of Millions of Women

Marc Beer has been an entrepreneur for well over 20 years. His ability to Develop unique solutions that solve immediate problems has allowed him to take numerous businesses to the pinnacle of success.

 

After graduating from Miami University in 1987, Beer took a position in the arena of pharmaceutical sales and marketing.

 

He was so good that he ended up getting promoted to Vice President of Global Marketing at Genzyme.

 

While serving as Vice President of Global Marketing, Beer realized he needed to up his game. He wanted to do more to address some of the issues the pharmaceutical industry couldn’t seem to solve.

 

In 2000 he stepped out on his own and launched his first company, ViaCell. Five years later the company went public and was listed on the NASDAQ as VIAC.

 

Two years after that, in 2007, PerkinElmer purchased ViaCell for $300 million. 

 

Beer’s New Mission To Improve The Lives of Millions of Women

 

After some time off to deal with the sudden death of his wife, Beer jumped back into the world of entrepreneurship. 

 

After a phone call from Dr. Ray Iglesias, Marc Beer knew exactly what his next move would be. 

 

In 2016 he co-founded Renovia, a Boston based med-tech company, with the help of Dr. Iglesias and Yolanda Lorié. 

 

Renovia’s main focus is on developing therapeutic and diagnostic devices that can be used to diagnose and treat women suffering from pelvic floor disorders.

 

The goal is to be able to provide first-line diagnosis and treatment, without the need for surgery.

 

Pelvic floor disorders affect about 25% of all women in the United States. They include conditions such as urinary incontinence, fecal incontinence, and pelvic organ prolapse.

 

With so many women suffering from pelvic floor disorders, Beer saw an opportunity to make a direct impact. 

 

In 2018, just two years after launching, Renovia had a year full of milestones. The biggest milestone was getting Leva, the company’s first product, approved by the FDA. 

 

Another big milestone was the acquisition of $32 million in Series B funding. The company also received $10 million in venture funding.

 

The funding will be used to better diagnose, treat, and improve the lives of millions of women who are currently dealing with pelvic floor disorders. Learn more: https://www.bloomberg.com/research/stocks/people/person.asp?personId=1285777&privcapId=47636573

 

By partnering with a digital health platform, Beer believes Renovia will not only be able to better treat and diagnose women but to also lower overall healthcare costs associated with pelvic floor disorders.

Follow Marc Beer on Facebook